Stock Monitor: AnaptysBio Post Earnings Reporting
LONDON, UK / ACCESSWIRE / March 29, 2018 / Active-Investors.com has just released a free research report on Nabriva Therapeutics PLC (NASDAQ: NBRV) (“Nabriva”). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=NBRV as the Company's latest news hit the wire. On March 27, 2018, the Company announced that it has collaborated with Roivant Sciences (“Roivant”) to develop and commercialize its lead product candidate, lefamulin, in greater China. Register today and get access to over 1,000 Free Research Reports by joining our site below:
Active-Investors.com is currently working on the research report for AnaptysBio, Inc. (NASDAQ: ANAB), which also belongs to the Healthcare sector as the Company Nabriva Therapeutics. Do not miss out and become a member today for free to access this upcoming report at:
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Nabriva Therapeutics most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
Details of the License Agreement
- Nabriva has granted one of Roivant's subsidiary an exclusive license to develop and commercialize lefamulin in the greater China region, specifically the People's Republic of China, Hong Kong, Macau, and Taiwan.
- The Roivant's affiliate will be solely responsible for all clinical development and regulatory filings necessary to secure approval in the covered territories.
- Both companies will establish a joint development committee to review and oversee all development and commercialization plans.
- Roivant will make an upfront payment of approximately $5 million to Nabriva along with approximately $90 million in additional payments tied to the successful completion of certain regulatory and commercial milestones related to lefamulin for community-acquired bacterial pneumonia (CABP).
- Additionally, Nabriva will be eligible to receive low double-digit royalties on sales upon approval in the covered territories.
Roivant has a Broad Therapeutic Portfolio and Deep Development and Commercialization Expertise
Dr. Colin Broom, Chief Executive Officer of Nabriva, stated that Roivant has a broad therapeutic portfolio and deep development and commercialization expertise, making the company an excellent partner as Nabriva pursue bringing an important and much-needed new treatment option for CABP and potentially other serious bacterial infections to China and surrounding territories. Dr. Colin added that the funding from this agreement will also contribute to the Company's efforts to prepare for a successful launch should lefamulin be approved in the United States.
Lefamulin Successful in Late-Stage CABP Study
In September 2017, Lefamulin completed LEAP 1 study, a pivotal, international Phase-3 clinical trial. The study evaluated the efficacy and safety of intravenous (IV) to oral lefamulin in adult patients with moderate to severe CABP compared to moxifloxacin with or without adjunctive linezolid. In LEAP 1, lefamulin met both the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) primary endpoints of non-inferiority compared to moxifloxacin with or without adjunctive linezolid.
Nabriva Anticipates Filing NDA in the Second Half of 2018
In the US, Nabriva anticipates filing a New Drug Application (NDA) in the second half of 2018 contingent on positive results from its second, pivotal Phase-3 clinical trial of lefamulin for CAPB, which is referred to as LEAP 2. Top-line data from LEAP 2 is expected in the spring of 2018. LEAP 2 is designed to assess the efficacy and safety of oral lefamulin compared to oral moxifloxacin in adult patients with moderate CABP.
About Community-Acquired Bacterial Pneumonia
CABP refers to pneumonia contracted by a person with little contact with the healthcare system. CABP is a leading cause of illness and death worldwide. Its causes include bacteria, viruses, fungi, and parasites. Symptoms and signs are fever, cough, sputum production, pleuritic chest pain, dyspnea, tachypnea, and tachycardia. Diagnosis is based on clinical presentation and chest x-ray.
Lefamulin is a semi-synthetic derivative of pleuromutilin that inhibits a key process for bacterial growth. In pre-clinical studies, lefamulin has demonstrated a targeted spectrum of activity against pathogens that most commonly cause CABP, including multi-drug resistant strains. Due to its novel mechanism of action, low incidence of cross-resistance between other antibacterial agents commonly used to treat CABP, and low propensity for bacterial resistance to develop, lefamulin has the potential to be used as a first-line empiric monotherapy for the treatment of CABP.
About Nabriva Therapeutics PLC
Established in 2006 and headquartered in Vienna, Austria, Nabriva Therapeutics is a clinical-stage biopharmaceutical company engaged in the research and development of novel antibiotics to treat serious infections, with a focus on the pleuromutilin class of antibiotics.
About Roivant Sciences
Roivant Sciences is a global healthcare company focused on realizing the full value of promising biomedical research to improve the lives of patients and their families. The Company's mission is to reduce the time and cost of developing new medicines for patients. Roivant was founded in 2014 and is headquartered in Basel, Switzerland.
Stock Performance Snapshot
March 28, 2018 - At Wednesday's closing bell, Nabriva Therapeutics' stock slightly climbed 0.60%, ending the trading session at $5.03.
Volume traded for the day: 197.54 thousand shares.
After yesterday's close, Nabriva Therapeutics' market cap was at $188.63 million.
The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 0.7% at the end of the session.
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.